Further, the simultaneous suppression of METTL3 and METTL14 has also been demonstrated to augment the efficacy of anti‐PD‐1 therapy in colorectal cancer and melanoma, owing to the higher infiltration of CD8+ T cells and massive cytokine release in the TIME.108. This evidence concerns the gene METTL3 and colorectal cancer.